OSE Immunotherapeutics SA (0RAD.L)
- Previous Close
5.48 - Open
5.58 - Bid --
- Ask --
- Day's Range
5.56 - 5.58 - 52 Week Range
2.73 - 7.31 - Volume
331 - Avg. Volume
2,675 - Market Cap (intraday)
740,650 - Beta (5Y Monthly) 0.78
- PE Ratio (TTM)
-- - EPS (TTM)
-0.93 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren's Syndrome; and FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis. The company is also developing BI 765063, which is in Phase I clinical trial to treat solid tumors; OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation; CLEC-1, a therapeutic target in immune-oncology and identified monoclonal antibody antagonists; and BiCKI, a novel bispecific checkpoint inhibitor platform that targets PD-1 to fight primary and secondary resistance mechanisms developed by cancers. OSE Immunotherapeutics SA has collaborations and partnerships with GERCOR, ARCAGY-GINECO, Foundation FoRT, and Nantes University Hospital; and Boehringer Ingelheim, MabSilico, CKD, Servier, Veloxis Pharmaceuticals, and Chong Kun Dang Pharmaceutical Corporation. The company was formerly known as OSE Pharma SA and changed its name to OSE Immunotherapeutics SA in May 2016. OSE Immunotherapeutics SA was founded in 2012 and is headquartered in Nantes, France.
www.ose-immuno.com--
Full Time Employees
December 31
Fiscal Year Ends
--
Sector
--
Industry
Recent News: 0RAD.L
Performance Overview: 0RAD.L
Trailing total returns as of 4/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0RAD.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0RAD.L
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-16.53%
Return on Equity (ttm)
-82.70%
Revenue (ttm)
2.23M
Net Income Avi to Common (ttm)
-23M
Diluted EPS (ttm)
-0.93
Balance Sheet and Cash Flow
Total Cash (mrq)
18.67M
Total Debt/Equity (mrq)
199.35%
Levered Free Cash Flow (ttm)
-11.42M
Company Insights: 0RAD.L
0RAD.L does not have Company Insights